医学
内镜逆行胰胆管造影术
胰腺炎
置信区间
随机对照试验
生理盐水
麻醉
急性胰腺炎
前瞻性队列研究
临床终点
相对风险
外科
升
林格溶液
丸(消化)
胃肠病学
内科学
作者
Chang‐Hwan Park,Woo Hyun Paik,Eun Soo Park,Chan Sup Shim,Tae Hoon Lee,Changdon Kang,Myung Hwan Noh,Sun Young Yi,Jong Lee,Jong Jin Hyun,Jun Lee
出处
期刊:Endoscopy
[Thieme Medical Publishers (Germany)]
日期:2017-12-13
卷期号:50 (04): 378-385
被引量:99
标识
DOI:10.1055/s-0043-122386
摘要
Abstract Background and study aims The present study aimed to determine the type of intravenous hydration that is best suited to reducing the incidence of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. Patients and methods In a prospective randomized multicenter trial, average-to-high risk patients who underwent first-time ERCP were randomly assigned to three groups (1:1:1) who received: aggressive intravenous hydration (3 mL/kg/h during ERCP, a 20-mL/kg bolus and 3 mL/kg/h for 8 hours after ERCP) with either lactated Ringer’s solution (LRS) or normal saline solution (NSS), or standard intravenous hydration with LRS (1.5 mL/kg/h during and for 8 hours after ERCP). The primary end point was post-ERCP pancreatitis (PEP). Results 395 patients were enrolled, and 385 completed the protocols. The three groups showed no significant differences in demographic characteristics. There was a significant difference in the intention-to-treat (ITT) PEP rate between the aggressive LRS group (3.0 %, 95 % confidence interval [CI] 0.1 % – 5.9 %; 4 /132), the aggressive NSS group (6.7 %, 95 %CI 2.5 % – 10.9 %; 9 /134) and the standard LRS group (11.6 %, 95 %CI 6.1 % – 17.2 %; 15 /129; P = 0.03). In the two-group comparisons, the ITT PEP rate was significantly lower for the aggressive LRS group than for the standard LRS group (relative risk [RR] 0.26, 95 %CI 0.08 – 0.76; P = 0.008). There was no significant difference in the ITT PEP rate between the aggressive NSS group and the standard LRS group (RR 0.57, 95 %CI 0.26 – 1.27; P = 0.17). Conclusion Aggressive hydration with LRS is the best approach to intravenous hydration for the prevention of PEP in average-to-high risk patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI